Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl T F, Balcke P
1st Medical Clinic, University of Vienna, Austria.
Nephron. 1991;59(3):399-402. doi: 10.1159/000186598.
The pharmacokinetics and dose response of recombinant human erythropoietin (rhEPO), administered intravenously and subcutaneously, were studied in chronic haemodialysis (HD) patients and in patients on chronic ambulatory peritoneal dialysis (CAPD). Furthermore, two products differing in the presence of albumin as preservative were compared. Although the pharmacokinetics differed after intravenous and subcutaneous administration, the dose response was the same. There is no statistically significant difference in the pharmacokinetics between the rhEPO in HD and CAPD, nor had the presence of albumin as preservative an influence on the pharmacokinetics.
在慢性血液透析（HD）患者和持续性非卧床腹膜透析（CAPD）患者中，研究了静脉内和皮下给予重组人促红细胞生成素（rhEPO）的药代动力学和剂量反应。此外，还比较了两种因含有白蛋白作为防腐剂而不同的产品。尽管静脉内和皮下给药后的药代动力学有所不同，但剂量反应是相同的。HD患者和CAPD患者使用的rhEPO在药代动力学上没有统计学上的显著差异，白蛋白作为防腐剂的存在对药代动力学也没有影响。
